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n anaphase, the spindle dictates the site of contractile
ring assembly. Assembly and ingression of the con-
tractile ring involves activation of myosin-II and actin
polymerization, which are triggered by the GTPase
RhoA. In many cells, the central spindle affects division
plane positioning via unknown molecular mechanisms.
Here, we dissect furrow formation in human cells and
show that the RhoGEF ECT2 is required for cortical local-
ization of RhoA and contractile ring assembly. ECT2
concentrates on the central spindle by binding to central-
spindlin. Depletion of the centralspindlin component
I
 
MKLP1 prevents central spindle localization of ECT2;
however, RhoA, F-actin, and myosin still accumulate on
the equatorial cell cortex. Depletion of the other central-
spindlin component, CYK-4/MgcRacGAP, prevents corti-
cal accumulation of RhoA, F-actin, and myosin. CYK-4
and ECT2 interact, and this interaction is cell cycle regu-
lated via ECT2 phosphorylation. Thus, central spindle lo-
calization of ECT2 assists division plane positioning and
the CYK-4 subunit of centralspindlin acts upstream of
RhoA to promote furrow assembly.
 
Introduction
 
Shortly after the metaphase–anaphase transition, cells must
ensure that the spindle poles are on opposite sides of the divi-
sion plane so that the segregated sets of chromosomes are
partitioned into separate cells. In some cells, such as budding
and fission yeast, division plane positioning precedes
anaphase onset, in which case the cell must coordinate the
position of the spindle with the preexisting division plane. In
contrast, in animal cells, the division plane is determined at
the metaphase to anaphase transition and its position is dic-
tated by the spindle. In animal cells, the spindle can regulate
division plane establishment by at least two distinct pathways
(for review see Glotzer, 2004). One pathway involves the
central spindle, a set of antiparallel microtubule bundles that
assembles during anaphase. A second pathway involves as-
tral microtubules. The relative importance of these two path-
ways differs among organisms. Despite the fundamental im-
portance of the process, no molecular pathway has yet been
defined that explains how the anaphase spindle positions the
division plane.
In animal cells, the GTPase RhoA has a central role in
furrow formation. When RhoA is depleted genetically or in-
activated by the bacterial enzyme C3, furrow formation is
abrogated (Kishi et al., 1993; Jantsch-Plunger et al., 2000).
The GTPase RhoA is involved in activating actin polymer-
ization by regulating formin proteins (Alberts, 2001), which
have a critical role in actin filament nucleation and elonga-
tion (Kovar et al., 2003; Romero et al., 2004). In addition,
RhoA can activate myosin by promoting phosphorylation of
myosin light chain (Kimura et al., 1996; Kosako et al.,
2000). Cleavage furrow formation might result from the lo-
cal activation of RhoA, which could promote key aspects of
contractile ring assembly.
RhoA is activated by guanine nucleotide exchange fac-
tors (GEFs) that stabilize the nucleotide-free, transition state of
small GTPases. There are large numbers of proteins containing
RhoGEF domains; these proteins have diverse biological
functions. One such RhoGEF, ECT2, originally identified as a
protooncogene (Miki et al., 1993), is a critical RhoGEF for
cytokinesis in animal cells. Overexpression of the NH
 
2
 
 termi-
nus of ECT2, lacking the GEF domain, inhibits completion of
cytokinesis in mammalian cells (Tatsumoto et al., 1999). Loss-
of-function studies confirm the requirement for ECT2. The
 
Drosophila melanogaster 
 
orthologue of ECT2, Pebble, is re-
quired for cytokinesis (Lehner, 1992; Prokopenko et al., 1999),
the 
 
Caenorhabditis elegans
 
 orthologue, LET-21, is likewise re-
quired for formation of a cleavage furrow (Dechant and
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Glotzer, 2003), and depletion of ECT2 prevents cytokinesis in
human cells (Kim et al., 2005).
ECT2 is an excellent candidate molecule to integrate the
spatial and temporal information that directs establishment of
the contractile ring. In vertebrate cells, ECT2 localizes to the
central spindle (Tatsumoto et al., 1999), which is implicated in
the spatial control of cytokinesis. Central spindle assembly and
completion of cytokinesis requires the centralspindlin complex
that consists of a Rho GTPase activating protein (GAP), CYK-
4/MgcRacGAP, and a kinesin-6, MKLP1 (Mishima et al.,
2002). In 
 
Drosophila
 
, the orthologue of ECT2, Pebble, binds to
the orthologue of CYK-4, RacGAP50C (Somers and Saint,
2003). This interaction was suggested to recruit Pebble/ECT2
to the vicinity of the central spindle where it could locally con-
trol formation of the contractile ring (Saint and Somers, 2003).
However, whether an ECT2–CYK-4 complex assembles in
other organisms is not known and, more importantly, the func-
tional significance of this complex has not been addressed.
In this study, we have developed a fluorescently tagged
RhoA protein whose cortical localization correlates with RhoA
activation. Using this probe and other tools, we have molecu-
larly dissected the requirements for RhoA localization to the
cell cortex during cytokinesis. We have found that the central
spindle restricts RhoA localization to a well defined region of
the equatorial cell cortex. However, the central spindle and the
localization of ECT2 to the central spindle are not strictly es-
sential for cortical RhoA localization. In contrast, the central-
spindlin component CYK-4 and the RhoGEF ECT2 are essen-
tial for RhoA localization and contractile ring assembly.
Furthermore, ECT2 associates with CYK-4 in a cell cycle–reg-
ulated manner. The interaction is weak during metaphase due
to mitotic phosphorylation of ECT2 and increases during ana-
phase when ECT2 is dephosphorylated. We propose that the
centralspindlin component CYK-4 can act as an essential acti-
vator of ECT2 that couples cytokinesis to mitotic exit.
 
Results
 
RhoA localizes in early anaphase
 
Genetic studies indicate that RhoA regulates cytokinesis by
controlling contractile ring formation. Biochemical pathways
are known through which RhoA promotes actin polymerization
and myosin activation. Because contractile ring formation oc-
curs at a discrete site, we investigated whether RhoA is spa-
tially regulated during cytokinesis. Under certain fixation
conditions, RhoA is highly concentrated at the site of contrac-
tile ring formation (Yonemura et al., 2004). We confirmed that
RhoA is discretely localized when cells are fixed with TCA
(Fig. 1 A), though not with formaldehyde or methanol (not de-
picted). The cortical domain of RhoA localization overlaps
extensively with the region where nonmuscle myosin IIB ac-
cumulates (Fig. 1 A). The cortical pool of RhoA appears to be
selectively retained during TCA fixation (unpublished data),
and this correlates well with the regions where its effectors are
active. This domain is positioned between the separating chro-
mosomes and is closely apposed to the central spindle during
early anaphase, as revealed by CYK-4 localization. Aurora B
kinase, which exhibits both central spindle and cortical local-
ization during early anaphase, is directly adjacent to the corti-
cal domain where myosin II concentrates (Fig. 1 A).
Because TCA fixation could induce the redistribution of
RhoA, we used another independent method to study RhoA lo-
calization. We examined the localization of a YFP-tagged vari-
ant of human RhoA. In cleaving HeLa cells, YFP:HsRhoA did
not localize distinctly during cytokinesis (Video 1, available at
http://www.jcb.org/cgi/content/full/jcb.200501097/DC1). How-
ever, YFP-tagged 
 
C. elegans
 
 RhoA (YFP:RhoA hereafter)
localized discretely in dividing HeLa cells and this pattern was
highly similar to the localization of endogenous RhoA in TCA-
fixed cells (Video 2, available at http://www.jcb.org/cgi/con-
tent/full/jcb.200501097/DC1; and Fig. 1, B and C). Human and
 
C. elegans
 
 RhoA are 96% similar (88% identical) and all but
two of the substitutions are in the COOH-terminal third of the
Figure 1. RhoA localizes to the equatorial cell cortex in early anaphase.
(A) HeLa cells were fixed with TCA and stained with antibodies directed
against RhoA (red) and either myosin IIB heavy chain or CYK-4 (green).
HeLa cells fixed with methanol were stained with antibodies directed
against aurora B (red) and tubulin or myosin II (green). (B) YFP:RhoA con-
centrates at the equatorial cortex before furrow formation. A HeLa cell stably
expressing YFP:RhoA is shown at successive time points during cytokinesis
(Video 2). This cell was treated with lamin B siRNA. (C) YFP:RhoA colocal-
izes with endogenous RhoA. Cells stably expressing YFP:RhoA were fixed
with TCA and stained with antibodies directed against RhoA (red) and
YFP (green). The anti-RhoA antibody does not cross react with YFP:RhoA.
(D) Cortical localization of YFP:RhoA increases upon RhoA activation and
decreases upon RhoA inhibition (arrows). The GAP domain of RhoGAP1
or the GEF domain of ECT2 were coexpressed with CFP in YFP:RhoA cells.
CFP-positive cells (inset) are indicated (asterisks). Images obtained from
the same cell are underlined. Bars: (A–C) 5  m; (D) 10  m. 
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protein. YFP:RhoA is functional in HeLa cells as indicated by
its ability to recruit myosin (Fig. S1 A, available at http://
www.jcb.org/cgi/content/full/jcb.200501097/DC1).
 
Cortical localization of YFP:RhoA 
correlates with RhoA activation
 
To test whether cortical YFP:RhoA reflects active RhoA, we
overexpressed either the GAP domain from mouse RhoGAP1 or
the COOH-terminal GEF domain from ECT2 and observed the
effects on YFP:RhoA localization in interphase HeLa cells (Fig.
1 D and Fig. S1 B). The signal from YFP:RhoA was diminished
and less cortical in cells that overexpress the GAP domain; these
cells also lack stress fibers (Fig. 1 D and Fig. S1 B). Conversely,
overexpression of the GEF domain induced enrichment of YFP:
RhoA at the cortex and an increase in stress fibers. (Fig. 1 D and
Fig. S1 B). Thus, the amount of cortically localized YFP:RhoA
correlates well with the activation level of RhoA.
 
RhoA is required for furrow formation 
and myosin recruitment
 
During cytokinesis, cortically localized YFP:RhoA colocalizes
with its downstream effectors, which is consistent with prior
genetic studies suggesting that RhoA is a critical regulator of
cytokinesis. Therefore, we addressed whether RhoA is func-
tionally required for the localization of actin and myosin II.
HeLa cells were treated with siRNAs directed against RhoA.
RhoA-depleted cells were cytokinesis defective (36% binucle-
ate, 
 
n
 
 
 
  
 
260 fixed cells). In anaphase cells lacking detectable
RhoA, actin (
 
n
 
 
 
 
 
 13/14 cells) and myosin II (
 
n
 
 
 
 
 
 22/24 cells)
failed to localize at the presumptive furrow (Fig. 2 A).
We next evaluated whether RhoA localization requires
myosin or actin. Blebbistatin, a small molecule inhibitor of my-
osin activity, causes a penetrant cytokinesis defect, as shown
previously (Straight et al., 2003). However, RhoA localized
normally in the presence of Blebbistatin (
 
n
 
 
 
 
 
 43) as did myo-
sin (
 
n
 
 
 
 
 
 14; Fig. 2 B). Similarly, depletion of the total pool of
myosin II using siRNAs also caused early cytokinesis defects
and prevented cell flattening during ana/telophase. RhoA accu-
mulation at the presumptive furrow was not affected by deple-
tion of myosin II (
 
n
 
 
 
 
 
 31; Fig. 2 B). Thus RhoA is required for
myosin II localization, but not vice versa. Next, we used La-
trunculin A (LatA), which causes actin filaments to disassem-
ble by sequestering actin monomers, to assess whether F-actin
is required for RhoA localization. Cells treated with LatA dis-
played early cytokinesis defects and loss of myosin localization
(
 
n
 
 
 
 
 
 20; Fig. 2 C). However, RhoA accumulated at the site of
the presumptive furrow as in nontreated cells (
 
n
 
 
 
 
 
 27; Fig. 2 C).
Thus, RhoA accumulates at the equatorial cortex independently
of actin and myosin. These data suggest that local accumula-
tion of RhoA may promote the assembly of actin filaments,
which are required in turn for myosin recruitment that is inde-
pendent of its motor activity.
Figure 2. RhoA regulates myosin II accumulation
and localizes in the absence of myosin II or F-actin.
(A) RhoA is required for accumulation of myosin II
and actin. HeLa cells depleted of RhoA were fixed
and stained with the indicated antibodies and
rhodamine phalloidin. (B) Neither myosin activity nor
myosin is required for RhoA localization. HeLa cells
were treated with 100  M Blebbistatin ( , active) or
Blebbistatin ( , inactive) for 45 min or treated with
siRNAs to myosin heavy chain before fixation and im-
munofluorescence. (C) F-actin is not required for RhoA
localization. HeLa cells treated with 5  M LatA for 45
min were fixed and stained with the indicated anti-
bodies and rhodamine phalloidin. Images obtained
from the same cell are underlined. Bars, 5  m. 
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ECT2 localizes to the central spindle
and is required for RhoA localization
and furrow formation
 
Because RhoA is an important early regulator of cytokinesis and
its localization, as measured by YFP:RhoA and by immunofluo-
rescence, correlates with active RhoA, we used RhoA localization
as an assay to investigate the mechanism that initiates cytokinesis.
In HeLa cells, during interphase, ECT2 and the centralspindlin
component CYK-4 are nuclear (Fig. 3 A). At anaphase onset,
ECT2 colocalizes with CYK-4 in the central spindle and remains
associated with the central spindle through furrow ingression un-
til the midbody stage (Fig. 3 A; Tatsumoto et al., 1999).
To confirm that human ECT2 is required for cytokinesis,
like its orthologues in 
 
Drosophila
 
 and 
 
C. elegans
 
, we used RNAi
to deplete endogenous ECT2 from HeLa cells. Penetrant cytoki-
nesis defects were observed as expected for an upstream regulator
of RhoA (92% binucleate, 
 
n
 
 
 
  
 
200 cells by fixed analysis). Time-
lapse imaging of ECT2-depleted cells revealed that the most se-
verely affected cells remained round during anaphase and did not
exhibit furrow ingression (Fig. 3 B and Videos 3 and 4, available
at http://www.jcb.org/cgi/content/full/jcb.200501097/DC1).
We next characterized the localization of RhoA and central-
spindlin in cells depleted of ECT2. Time-lapse analysis of YFP:
RhoA revealed that this reporter failed to localize in ECT2-
depleted cells (Video 5, available at http://www.jcb.org/cgi/
content/full/jcb.200501097/DC1; 
 
n
 
 
 
 
 
 11 noningressing cells). Im-
munofluorescence analysis of anaphase cells revealed that all cells
fully depleted of ECT2 failed to ingress (
 
n
 
 
 
 
 
 24). Cortical localiza-
tion of RhoA was abolished in all noningressing cells (
 
n
 
 
 
 
 
 24; in-
compatible fixation precluded costaining of ECT2 and RhoA;
Fig. 3 C). Myosin recruitment (
 
n
 
 
 
 
 
 14) and actin accumulation
(
 
n
 
 
 
 
 
 17) were also abolished in cells lacking ECT2 (Fig. 3 C).
However, centralspindlin localization was not affected in these
cells (Fig. 3 C). Similarly, centralspindlin and ECT2 localized in
cells depleted of RhoA (Fig. 2 A). These results demonstrate that
ECT2 is required for RhoA activation and contractile ring forma-
tion but central spindle assembly is independent of ECT2.
 
MKLP1 is required for central spindle 
assembly and ECT2 localization but not 
RhoA recruitment
 
Localization of ECT2 to the central spindle could regulate cleav-
age furrow formation by creating a localized pool of active RhoA,
as previously proposed (Somers and Saint, 2003). To test this
possibility, we depleted MKLP1 from HeLa cells using RNAi.
MKLP1 forms a heterotetramer with CYK-4 and is required for
central spindle formation (Mishima et al., 2002). Other investiga-
tors have demonstrated that cells depleted of MKLP1 do not form
a well organized central spindle, yet are able to form cleavage fur-
rows that ingress extensively and regress (Matuliene and
Kuriyama, 2002). As expected, loss of MKLP1 caused abnormal
central spindle formation and both CYK-4 (
 
n
 
 
 
 
 
 25) and ECT2
(
 
n
 
 
 
 
 
 43/47) failed to localize (Fig. 4 A). Interestingly, two
classes of cytokinesis phenotypes were observed in time-lapse
recordings of MKLP1-depleted cells. About 1/3 of cells (9/28)
displayed a late cytokinesis defect, as observed previously.
However, in the remaining cells, weak or no furrow formation
was observed. Importantly, RhoA was cortically localized in all
cells (Fig. 4 B). However, the domain of cortically localized
RhoA was expanded as compared with control cells (Fig. 4 B).
To quantify this difference, we measured the angle subtended by
the cortical region where RhoA concentrated in fixed cells.
MKLP1 depletion affected cell shape, therefore the cell dimen-
sions were measured and these parameters were plotted for each
cell (Fig. 5 A). Control cells were elliptical and the zone of RhoA
was quite restricted (Fig. 4 B and 5 A). MKLP1-depleted cells
that formed furrows were elliptical like the control cells, but the
RhoA zone was somewhat expanded (Fig. 4 B and 5 A). In con-
trast, cells without furrows were less elliptical and had the great-
est expansion of the RhoA zone (Fig. 4 B and 5 A).
To better correlate the extent of the zone of RhoA with the
phenotype of the cell, we performed time-lapse analysis of
MKLP1-depleted cells expressing YFP:RhoA and measured the
zone of RhoA during anaphase (Fig. 5 B and Videos 6 and 7,
available at http://www.jcb.org/cgi/content/full/jcb.200501097/
Figure 3. ECT2 localizes to the central spindle
and regulates RhoA localization and cytokinesis.
(A) ECT2 localizes to the central spindle and
colocalizes with the centralspindlin complex.
(B) ECT2 is required for furrow formation.
ECT2 depleted or control cells undergoing cy-
tokinesis were imaged by DIC microscopy
(Videos 3 and 4). (C) Neither RhoA, myosin,
nor actin localize to the cell cortex in ECT2-
depleted cells, but the central spindle assem-
bles normally. ECT2-depleted or control cells
were fixed and stained with the indicated anti-
bodies or rhodamine phalloidin. Images ob-
tained from the same cell are underlined.
Bars: (A, top) 10  m; (A–C) 5  m. 
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DC1). In control cells, YFP:RhoA localization was quantita-
tively similar to that of endogenous RhoA in fixed cells. Deple-
tion of MKLP1 caused an increase in the size of the YFP:RhoA
zone. The cells that formed furrows were more elliptical and
contained a more restricted zone of RhoA than cells that did not
furrow (Fig. 5, A and B). Immunofluorescence analysis of fixed
cells showed that myosin II (
 
n
 
 
 
 
 
 11) and actin (
 
n
 
 
 
 
 
 13) local-
ization were also expanded, implying that the extended pool of
localized RhoA is active (Fig. 4 B). These data suggest that the
central spindle is not required for cortical localization of active
RhoA, but, rather, it functions to restrict the zone of active
RhoA to a narrow region. Thus, failure to localize ECT2 to the
midzone results in a variable broadening of the RhoA zone that
can interfere with cleavage furrow formation.
 
Aurora kinase is required for central 
spindle assembly and furrow formation 
but not RhoA recruitment
 
To perturb the central spindle by an independent means to eval-
uate its involvement in restricting accumulation of active
RhoA, we depleted aurora B kinase by siRNAs or inhibited its
activity by treatment with the aurora inhibitor Hesperadin
(Hauf et al., 2003). Cells lacking aurora B activity displayed
variable cytokinesis defects, similar to cells lacking MKLP1.
In both live and fixed cells, aurora B inhibition induced ex-
pansion of the region of cortical RhoA localization (Fig. 5 C;
Videos 8 and 9, available at http://www.jcb.org/cgi/content/
full/jcb.200501097/DC1 [
 
n
 
 
 
 
 
 12 live cells]; and not depicted).
Furthermore, the same expansion of the zone of RhoA was ob-
served in time-lapse analysis of cells simultaneously depleted
of MKLP1 and treated with the aurora inhibitor (
 
n
 
 
 
 
 
 9 cells;
unpublished data). These data provide independent evidence
that the central spindle plays a role in refining the localization
of active RhoA to the site of the cleavage furrow.
 
CYK-4 is required for central spindle 
assembly, ECT2 localization, furrow 
formation, and RhoA recruitment
 
We next examined the consequences of CYK-4 depletion on
cytokinesis. In 
 
C. elegans
 
, CYK-4 is required for central spin-
dle formation and CYK-4–depleted embryos form ingressing
cleavage furrows that regress late in cytokinesis (Jantsch-
Plunger et al., 2000). HeLa cells depleted of detectable CYK-4
by RNAi failed to form a central spindle, and both ECT2 (
 
n
 
 
 
 
 
 15)
and MKLP1 (
 
n
 
 
 
 
 
 15) failed to localize. Strikingly, these cells
showed an early cytokinesis phenotype: the cells were round
and furrow formation did not occur. Importantly, RhoA failed
to accumulate at the cortex in both live and fixed cells lacking
CYK-4 (
 
n
 
 
 
 
 
 19 noningressing live cells; 
 
n
 
 
 
 
 
 45 fixed cells;
Fig. 6 and Video 10, available at http://www.jcb.org/cgi/
content/full/jcb.200501097/DC1). Actin (
 
n
 
 
 
 
 
 14) and myo-
sin (
 
n
 
 
 
 
 
 11) also failed to localize in CYK-4–depleted cells
(Fig. 6). The cytokinesis phenotype caused by CYK-4 deple-
tion closely parallels that caused by loss of ECT2, suggesting
that CYK-4 may regulate RhoA activation and thereby con-
tractile ring assembly. This function of CYK-4 does not ap-
pear to be shared by its partner protein in the centralspindlin
complex, MKLP1.
 
CYK-4 binds to ECT2 in a 
phosphoregulated manner
 
As mentioned previously, the 
 
Drosophila
 
 orthologues of
ECT2 and CYK-4 interact in a yeast two-hybrid assay as well
as in embryo extracts (Somers and Saint, 2003). These obser-
vations prompted us to determine if endogenous ECT2 and
CYK-4 interact in human cells. Indeed, CYK-4 coimmunopre-
cipitated with ECT2 from mitotic HeLa cell lysates (Fig. 7 A).
Significantly more CYK-4 coprecipitated with MKLP1, sug-
gesting that only a fraction of the centralspindlin complex as-
sociates with ECT2.
In addition to the GEF domain, ECT2 also contains
two BRCA1 COOH terminus (BRCT) domains in its NH
 
2
 
-
terminal region, which are predicted to mediate protein–protein
interactions. Therefore, we determined if the ECT2 BRCT
domains are sufficient to bind to CYK-4. Using recombinant
fragments, we found that ECT2 could efficiently bind to im-
mobilized CYK-4 NH
 
2
 
 terminus, whereas a control fusion
protein and empty beads bound only trace amounts of ECT2
(Fig. 7 B).
Figure 4. MKLP1 is required for ECT2 localization. (A) Cells depleted of
MKLP1 were fixed and stained with the indicated antibodies. (B) MKLP1
restricts the localization of RhoA, but it does not block cortical localization
of RhoA. MKLP-depleted cells were fixed and stained with the indicated
antibodies or rhodamine phalloidin. Cells that exhibit the two classes of
cytokinesis phenotypes are shown. Bars, 5  m. 
JCB • VOLUME 170 • NUMBER 4 • 2005 576
 
To more precisely define the region of ECT2 that binds to
CYK-4, we prepared a set of truncation derivatives and pro-
duced the fusion proteins in 
 
E. coli
 
 (Fig. 7 C). These deriva-
tives were used as affinity reagents to bind factors in mitotic
lysates from HeLa cells. The NH
 
2
 
-terminal region of ECT2
was sufficient to pull-down CYK-4 (Fig. 7 D). ECT2 frag-
ments containing both BRCT domains (E3, E4, and E5) re-
trieved significantly more CYK-4 in comparison to fragments
containing only the first BRCT domain (E1); the second BRCT
domain (E2) did not retrieve detectable CYK-4. Moreover, we
observed that, like endogenous ECT2, truncation derivative E5
localized to the central spindle during anaphase (Fig. 7 E).
Recent studies suggest that tandem BRCT domains con-
stitute a phosphopeptide binding domain (Manke et al., 2003).
Therefore, we determined if the ability of recombinant ECT2 to
associate with CYK-4 from mitotic lysates required phosphor-
ylation of proteins in the lysate. Proteins in the lysate were de-
phosphorylated before the pull-down with recombinant ECT2
Figure 5. Expansion of cortically localized
RhoA upon MKLP1 depletion and aurora inhi-
bition. (A) Quantitation of RhoA localization
in MKLP1-depleted cells and control cells. Cell
morphology and the extent of RhoA localiza-
tion in fixed and live cells were measured as
indicated. Fixed cells were scored for the pres-
ence of a furrow and live cells were scored for
furrow formation during the course of the re-
cording. Fixed cells with partly condensed,
and segregated DNA were measured. Live
cells were measured when RhoA localization
was most restricted. (B) YFP:RhoA-expressing
cells were depleted of MKLP1 by RNAi. YFP:
RhoA was imaged and shown at successive
time points during cytokinesis. Two pheno-
types were observed. Either RhoA remained
somewhat restricted and these cells formed
furrows that regress; otherwise RhoA spread
out along the cell cortex and furrows did not
form (Videos 6 and 7). (C) HeLa cells stably ex-
pressing YFP:RhoA were treated with 100 nM
Hesperadin and YFP:RhoA was imaged during
cytokinesis (Videos 8 and 9). Bars, 5  m.
Figure 6. CYK-4 is required for central spin-
dle formation and is essential for active RhoA
localization. Cells depleted of CYK-4 were
fixed and stained with the indicated antibod-
ies or rhodamine phalloidin. YFP:RhoA local-
ization was also abolished in CYK-4–depleted
cells (Video 10). Images obtained from the
same cell are underlined. Bars, 5  m. 
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fragment E3. Fragment E2 was used as a negative control.
Phosphatase treatment significantly reduced the ability of
fragment E3 to bind to CYK-4 (Fig. 7 F). Thus, the association
between ECT2 and CYK-4 is enhanced by phosphorylation.
Because the ECT2 fragments used in this assay were bacteri-
ally expressed and are unlikely to be phosphorylated, a protein
in the lysate must be phosphorylated for efficient binding of
CYK-4 to ECT2. Because CYK-4 binds directly to ECT2, this
protein could be CYK-4 itself.
 
CYK-4–ECT2 binding is cell cycle 
regulated
 
Next, we investigated whether the abundance of the ECT2–
CYK-4 complex is regulated during mitosis. Lysates were
prepared from metaphase-arrested cells and at intervals after
release from metaphase. ECT2 was immunoprecipitated and
the associated proteins were analyzed by Western blotting. The
association between CYK-4 and ECT2 was not detectable in
metaphase extracts. However, 60 min after release from
metaphase, when most cells are in early anaphase, the abun-
dance of the ECT2–CYK-4 complex increased dramatically
(Fig. 8 A). Using an anti–phospho-TP antibody, we found that
ECT2 was phosphorylated in metaphase. The phospho-TP sig-
nal on ECT2 decreased concomitantly with an increase in
abundance of the ECT2–CYK-4 complex (Fig. 8 A). To deter-
mine whether CDK1 activity acutely inhibits the ECT2–CYK-4
interaction during metaphase, we treated nocodazole-arrested
cells with Roscovitine, an inhibitor of CDK1. Roscovitine
treatment significantly increased the association between ECT2
and CYK-4 (Fig. 8 B). These data indicate that ECT2–CYK-4
complex formation is inhibited during metaphase and this inhi-
bition is relieved in anaphase. The inhibitor studies implicate
CDK1 as a negative regulator of this interaction.
 
Metaphase phosphorylation of ECT2 
inhibits CYK-4 binding
 
We sought to understand the molecular mechanism that regu-
lates the abundance of the ECT2–CYK-4 complex. Perhaps the
phosphorylated residue recognized by the BRCT domains of
ECT2 is absent in metaphase and accumulates in anaphase. Al-
ternatively, CYK-4 may be phosphorylated but contains an addi-
tional modification during metaphase that inhibits its association
with ECT2. To test these two possibilities, we used bacterially
expressed ECT2 fragments to pull-down proteins from lysates
prepared at metaphase and at various times during anaphase
and analyzed the associated proteins by Western blotting. Re-
combinant ECT2 NH
 
2
 
 terminus (E3) pulled down equivalent
amounts of CYK-4 from metaphase and anaphase extracts
(Fig. 8 C), suggesting that in metaphase CYK-4 has the modi-
fications necessary to bind to ECT2 and does not contain
modifications that prevent this interaction.
A third possibility is that ECT2–CYK-4 complex forma-
tion may be inhibited during metaphase via regulation of
ECT2. Because the phospho-TP signal on ECT2 inversely cor-
relates with CYK-4 binding, we prepared myc-tagged ECT2
fragments (Fig. 9 A) to identify the metaphase-specific phos-
Figure 7. CYK-4 and ECT2 directly interact and associate in vivo in a
phosphorylation-dependent manner. (A) ECT2, CYK-4, and MKLP1 were
precipitated and the immunoprecipitates were subjected to Western blot-
ting with anti–CYK-4 antibodies. (B) Recombinant, soluble ECT2 E5 was
incubated with CBD beads or CBD beads bound to CBD-CYK-4-N or CBD-
CSC-1. Bound proteins were analyzed by Coomassie staining. (C) Sche-
matic showing the boundaries of deletion constructs. (D) The tandem BRCT
domains are sufficient for efficient binding of CYK-4. E. coli–expressed
derivatives bound to chitin beads were used to pull-down proteins from a
mitotic cell lysate. Bound proteins were analyzed by Western blotting with
anti–CYK-4 antibodies. (E) The ECT-2 truncation derivative E5 colocalizes
with CYK-4. Myc-tagged ECT2 E5 construct was transfected into HeLa
cells, fixed, and stained for myc and CYK-4. (F) The association between
CYK-4 and the ECT2 BRCT domains is phosphodependent. Mitotic cell ly-
sates were treated with   phosphatase before binding to chitin beads
loaded with the indicated proteins. Bound proteins were analyzed by
Western blotting with anti–CYK-4 antibodies.
Figure 8. The association between CYK-4 and ECT2 is cell cycle regulated.
(A) Time course analysis of the association of CYK-4 and ECT2 during mi-
totic exit. HeLa cells were arrested in metaphase with nocodazole and
released. Lysates were prepared at the indicated times and ECT2 was
immunoprecipitated. Immunoprecipitates were Western blotted with anti–
CYK-4 and anti–phospho-Thr-Pro antibodies to detect phosphorylation of
ECT2. (B) CDK1 activity antagonizes the interaction between CYK-4 and
ECT2. Metaphase-arrested HeLa cells were treated with Roscovitine for 30
min, ECT2 was immunoprecipitated, and the immunoprecipitates were
Western blotted with anti–CYK-4 antibodies. (C) Recombinant ECT2 pulls
down CYK-4 equally efficiently in metaphase and anaphase. HeLa cells
were arrested in metaphase with nocodazole and released from the arrest.
Lysates were prepared at the indicated times and ECT2 binding proteins
were recovered with chitin beads loaded with the E3 fusion protein.
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pho-TP site to test whether this phosphorylation regulates com-
plex formation. We transfected cells with myc-tagged versions
of the NH2- and COOH-terminal halves of ECT2. The cells
were arrested in metaphase and lysates were collected at
metaphase and at various times after release. The expressed
proteins were immunoprecipitated and analyzed by Western
blotting with the anti–phospho-TP antibody. The NH2-terminal
half (E5) was highly phosphorylated in metaphase and was de-
phosphorylated as the cells entered anaphase (Fig. 9 B). The
COOH-terminal half did not react strongly with the antibody.
To narrow down the region, we prepared additional deletion
constructs (Fig. 9 A). These constructs were transfected into
HeLa cells that were subsequently arrested in metaphase and
the tagged proteins were immunoprecipitated. In metaphase
cells, fragment E5 was reactive with the phospho-TP antibody
and did not coprecipitate significant amounts of CYK-4 (Fig. 9
C). In contrast, the slightly shorter fragment, E4, did not react
with the phospho-TP antibody and precipitated significantly
more CYK-4 (Fig. 9 C). Thus, the association between ECT2
and CYK-4 inversely correlates with mitotic phosphorylation
of ECT2.
To obtain direct evidence that mitotic phosphorylation of
ECT2 inhibits its association with CYK-4, we mutated threo-
nine 342, which is one of the TP sites in the region that distin-
guishes fragments E4 and E5, to alanine in fragment E6, which
comprises residues 1–352. E6, E6* (T342A), and fragment E4
were transfected into HeLa cells. The cells were arrested in
metaphase and the tagged proteins were immunoprecipitated.
Fragment E6 was reactive with the phospho-TP antibody and
did not precipitate significant amounts of CYK-4 (Fig. 9 C).
However, E6*(T342A) did not react with the phospho-TP anti-
body and, importantly, this mutant precipitated significantly
more CYK-4 than E6. These data indicate that T342 is phos-
phorylated during metaphase and this phosphorylation inhibits
ECT2 from binding to CYK-4. To summarize, the ability of the
NH2 terminus of ECT2 to bind a phosphoprotein, probably
CYK-4, inhibited phosphorylation of ECT2 in metaphase.
Discussion
We have investigated the molecular requirements for cleavage
furrow formation in cultured human cells. We report that the
central spindle–associated RhoGEF ECT2 is required for corti-
cal localization of the GTPase RhoA and for accumulation of
two major constituents of the contractile ring, myosin II and
F-actin. Depletion of the centralspindlin component MKLP1
causes delocalization of ECT2, and yet RhoA, F-actin, and my-
osin accumulate on the cell cortex and, when the cortical zone
of RhoA localization is sufficiently narrow, cleavage furrow
formation occurs. Thus, central spindle localization of ECT2 is
not required for furrow formation. In contrast, depletion of the
centralspindlin component CYK-4 prevents cortical localiza-
tion of RhoA, actin, and myosin and prevents cleavage furrow
formation. Therefore, in human cells, CYK-4 acts upstream of
RhoA. CYK-4 binds directly to ECT2 and this interaction is
cell cycle regulated. We propose that CYK-4 activates the
RhoGEF activity of ECT2, which promotes activation of
RhoA. ECT2 localization to the central spindle helps restrict
RhoA activity to the equatorial cell cortex at anaphase. However,
ECT2 can activate RhoA globally and additional mechanisms
contribute to equatorial localization of RhoA.
Spatial regulation of RhoA
Cytokinesis begins at the metaphase to anaphase transition. At
this time, components of the central spindle are activated by
dephosphorylation. Non-kinetochore, antiparallel microtu-
bules are bundled by kinesin motors including the centralspin-
dlin complex and several microtubule-associated proteins, in
particular PRC1 (for review see Glotzer, 2005). In HeLa cells,
these bundles, and therefore centralspindlin and ECT2, are
most abundant in the center of the cell. However, these bundles
are also present in the subcortical cytoplasm underlying the
region where RhoA concentrates. Cortical RhoA recruitment
requires ECT2, and this pool of RhoA colocalizes with myosin
II and actin, suggesting that it is active. The actin and myosin
that are recruited by RhoA then participate in contractile ring
assembly leading to cleavage furrow formation.
Due to their overlapping localization patterns, central-
spindlin was proposed to recruit Pebble/ECT2 to the cell cortex
overlying the central spindle where the exchange factor could
activate RhoA (Somers and Saint, 2003). We tested this ap-
pealing hypothesis by depleting MKLP1 and by inhibiting au-
rora B kinase, two treatments that result in delocalization of
CYK-4 and ECT2. A significant fraction of such cells form
Figure 9. Identification of a phosphorylation site that regulates the CYK-4–
ECT-2 interaction. (A) Schematic of the ECT2 constructs used. (B) The NH2-
and COOH-terminal halves (E5 and C-term) of ECT2 were transfected into
HeLa cells, which were then arrested in metaphase with nocodazole. Cells
were released from the block and collected at the indicated times. The myc-
tagged ECT2 constructs were immunoprecipitated and Western blotted with
anti-myc and anti–phospho-Thr-Pro antibodies. (C) ECT2 fragments are
differentially competent to bind CYK-4 during metaphase. The differential
association inversely correlates with reactivity with anti–phospho-Thr-Pro
antibody. ECT2 constructs were transfected into HeLa cells, which were
then arrested in metaphase with nocodazole. Lysates were prepared and
the myc-tagged ECT2 constructs were immunoprecipitated and Western
blotted  with anti-CYK-4, anti-myc, and anti–phospho-Thr-Pro antibodies.
(D) Identification of threonine 342, which, when mutated to alanine, pre-
vents TP phosphorylation and allows ECT2 to bind CYK-4 during
metaphase. This experiment was performed as described in C.SPATIAL AND TEMPORAL REGULATION OF RHOA • YÜCE ET AL. 579
cleavage furrows that later regress, whereas other cells do not
form furrows. In all cells, RhoA is cortically localized and ac-
tin and myosin accumulate. We observed that cells in which
RhoA was more restricted (though slightly broader than control
cells) form furrows, whereas cells in which the RhoA zone was
greatly expanded do not form furrows. These data suggest that
furrow formation will not occur if the actively constricting
zone exceeds a certain size. Because cortical localization of
RhoA requires ECT2, we conclude that delocalized ECT2 is
active. These results are consistent with previous observations
in which disruption of the central spindle by depletion of either
MKLP1 or PRC1 did not abrogate cleavage furrow formation
(Matuliene and Kuriyama, 2002; Mollinari et al., 2004). The
ability to follow cortical RhoA localization in living cells has
enabled us to extend these observations. In particular, we have
shown that localization of ECT2 to the central spindle contrib-
utes to spatial regulation of RhoA, but it is not the sole means
by which RhoA activity is localized (Fig. 10).
How does RhoA become cortically localized when ECT2
is not concentrated on the central spindle, as in MKLP1-depleted
cells? In C. elegans, we have demonstrated that two pathways re-
dundantly specify furrow formation (Dechant and Glotzer,
2003). One pathway relies on the central spindle and the second
involves astral microtubules. In several biological contexts, mi-
crotubules inhibit cortical contractility (Danowski, 1989; Ren et
al., 1999; Pletjushkina et al., 2001), and because the density of
astral  microtubules is higher at the polar cortex than at the
equatorial cortex, this would result in increased equatorial con-
tractility and allow formation of an ingressing cleavage furrow.
Importantly, cytokinesis is delayed when only one pathway is
operable, indicating that both pathways are active in wild-type
embryos. By analogy, we suspect that, in MKLP1-depleted
human cells, as in C. elegans embryos lacking ZEN-4/MKLP1,
astral microtubules regulate cortical contractility.
Mode of RhoA activation
Both ECT2 and CYK-4 are required for cortical localization of
RhoA, accumulation of F-actin and myosin, and furrow forma-
tion. The biochemical mechanism by which ECT2 activates
RhoA is well defined: it induces exchange of GDP for GTP on
RhoA. How does CYK-4 activate RhoA? This may involve in-
tramolecular autoinhibition of ECT2, as has been seen previ-
ously in other GEFs (Aghazadeh et al., 2000). Consistent with
this idea, the NH2 terminus of ECT2 binds to and inhibits the
COOH-terminal GEF domain (Saito et al., 2004; Kim et al.,
2005). We have shown that the NH2 termini of ECT2 and
CYK-4 interact directly in vitro. Based on the precedence for
intramolecular inhibition of RhoGEFs, it is tempting to specu-
late that CYK-4 activates ECT2 by relieving its autoinhibition
(Fig. 10).
It is remarkable that CYK-4, which contains a RhoGAP
domain, appears to activate a RhoGEF. If the GEF activity of
ECT2 activates RhoA, what would prevent the RhoGAP do-
main from CYK-4 from immediately inactivating RhoA, lead-
ing to a futile cycle? The solution to this apparent paradox
could come from the fact that CYK-4 has a low GAP activity
toward RhoA. Thus, in the ECT2–CYK-4 complex, the balance
of activities may favor RhoA activation. The GAP domain of
CYK-4 may act on another GTPase, such as Rac or Cdc42
(D’Avino et al., 2004; Oceguera-Yanez et al., 2005), or it may
not be of great importance to cytokinesis (Goldstein et al.,
2005), or it may function late in division when the nature of the
ECT2–CYK-4 complex changes. The potential of a futile cycle
is more acute for Rac and Cdc42 because, in vitro, ECT2 acti-
vates all three GTPases to a similar extent (Tatsumoto et al.,
1999) and CYK-4 is  30-fold more active against Rac and
Cdc42 than RhoA (Toure et al., 1998). Further analysis of the
role of the CYK-4 GAP domain will be important to fully un-
derstand this interesting question.
Temporal regulation of RhoA
The interaction between ECT2 and CYK-4 is regulated by at
least two phosphorylation events. First, phosphorylation of a
factor, likely CYK-4, enhances the binding of CYK-4 to the
tandem BRCT domains of ECT2. Recombinant ECT2 can
pull-down CYK-4 from lysates at all stages of mitosis so this
phosphorylation is not highly regulated. In contrast, the inter-
action between endogenous CYK-4 and ECT2 is cell cycle
regulated; it is reduced in metaphase as compared with ana-
phase. This regulation is due, at least in part, to phosphoryla-
tion of ECT2 at threonine 342. Phosphorylation of ECT2
T342, adjacent to the second BRCT domain, inhibits its bind-
ing to CYK-4 during metaphase (Fig. 10). The kinase responsi-
ble has not been unambiguously identified. However, we favor
the interpretation that CDK1 is responsible because T342 is
strongly phosphorylated in metaphase and is dephosphory-
lated upon anaphase onset, and a CDK1 inhibitor enhances
ECT2–CYK-4 complex formation. Although this site
(SLMTPNSNK) does not have a basic residue in the  2 or
 3 position as is commonly found in CDK1 sites, other
CDK1 sites are known that lack the basic residue (Yamashiro
et al., 1995; Esashi et al., 2005). Negative regulation of ECT2
Figure 10. The phenotypes of depleted cells and the regulated association
of CYK-4 and ECT2. (A) A schematic model summarizing the phenotypes
of cells depleted of MKLP1, CYK-4, and ECT2. (B) A model for the regu-
lated association of CYK-4 and ECT2. See text for details.JCB • VOLUME 170 • NUMBER 4 • 2005 580
by CDK1 is consistent with several previous results. In Dro-
sophila, nondegradable cyclin derivatives, which prolong
CDK1 activity, antagonize mutations in the Pebble gene
(Echard and O’Farrell, 2003). Furthermore, high CDK1 lev-
els have been shown to inhibit cortical recruitment of myosin
II (Royou et al., 2002). Finally, measurements of RhoA•GTP
levels in human cells indicate that the levels of active RhoA
increase from metaphase to anaphase (Kimura et al., 2000).
These earlier findings are all consistent with CDK1-mediated
inhibition of ECT2 activation by CYK-4.
Applicability to other systems
The regulatory mechanisms described here may apply in
other animal cells, though perhaps not in all details. The cor-
tical localization of RhoA to the nascent furrow appears
widely conserved. The distribution of YFP:RhoA that we
have observed in living cells resembles the localization of
RhoA in fixed vertebrate cells (Yonemura et al., 2004) and
of a GFP:RBD fusion protein that binds specifically to
RhoA•GTP (Bement et al., 2005). Given the well docu-
mented requirement for RhoA in cytokinesis and its ability to
regulate actin polymerization and myosin activity, local ac-
cumulation of active RhoA may be a general mechanism for
furrow formation.
However, the regulatory mechanisms responsible for
the spatial and temporal regulation of RhoA may differ
somewhat in other systems. For example, in C. elegans em-
bryos, furrow formation occurs when CYK-4 is depleted, in-
dicating that CYK-4 is not an essential activator of the ECT2
orthologue LET-21. If the role of CYK-4 in human cells is to
engage the tandem BRCT domains of ECT2 and relieve au-
toinhibition, perhaps in C. elegans other factors serve this
function.
Drosophila differs from mammalian cells in that the
ECT2 orthologue Pebble does not localize to the central spin-
dle. Rather, this critical GEF localizes to a ring in the cell cor-
tex (Prokopenko et al., 1999). Because Pebble and RacGAP50C/
CYK-4 interact in Drosophila (Somers and Saint, 2003), it is
not clear why Pebble does not accumulate on the central
spindle. Most importantly, it is not yet known if Pebble lo-
calization requires either component of the centralspindlin
complex, Pav/MKLP1 or RacGAP50C. Drosophila also differs
from human cells and C. elegans embryos in that the assembly
of a contractile ring requires the MKLP1 orthologue Pavarotti
(Adams et al., 1998). The basis for this requirement is not
known. The central spindle–independent pathway observed in
human cells and C. elegans embryos may be absent in Dro-
sophila, which would predict global RhoA recruitment. Alter-
natively, if loss of Pavarotti destabilized the CYK-4 ortho-
logue, then the Pavarotti mutants would fail to recruit cortical
RhoA and resemble the CYK-4–depleted cells shown here.
Although the basic machinery for cytokinesis is con-
served, differences do exist in different cell types. In addition,
cytokinesis is affected by the degree to which cells are attached
to the substrate. Further analysis at the biochemical and in vivo
at the molecular level using probes like the one presented here
will help to assess the generality of this mechanism.
Materials and methods
Cell culture
HeLa cells were grown in DME supplemented with 10% FCS, 2 mM L-glu-
tamine, 100 U penicillin, and 0.1 mg/ml streptomycin. LipofectAmine
PLUS reagent (Invitrogen) was used for DNA transfections.
Antibodies
The following commercial antibodies were used. For immunostaining,
primary antibodies were a follows: mouse anti-RhoA and rabbit anti-
RhoA (Santa Cruz Biotechnology, Inc.) and rabbit anti-MHC (nonmuscle
IIB; Sigma-Aldrich) were used at 1:100; aurora B (Transduction labs),
rhodamine phalloidin (Molecular Probes), DM 1  monoclonal anti–
 -tubulin (Sigma-Aldrich), and monoclonal anti-GFP mixture (clone 7.1
and 13.1; Roche) were used at 1:300, rat anti-tubulin YOL/34 was
used at 1:50. Alexa-labeled secondary antibodies (Molecular Probes)
were used at 1:500. For Western blotting, anti-phospho-Thr-Pro (Cell
Signaling Technology) and rabbit anti-Myc (CM-100; Gramsch Labs)
were used at 1:500 and 1:1,000, respectively.
An ECT2 antibody was raised in rabbits immunized with recombi-
nant ECT2 (1–421) and affinity purified. Rabbit and mouse anti–HsCYK-4
and anti–HsMKLP-1 were described previously (Mishima et al., 2002).
RNA interference and drug treatments
We used siRNA duplexes targeting the following sequences for RNA-
mediated inhibition: RhoA, GCCGGUGAAACCUGAAGAA; MHC, CU-
GUAUCCUGCUUCAGACU; ECT2, GGCGGAAUGAACAGGAUUU;
CYK-4, CCUCUUCUGACCUUUCGCC; MKLP1, CGACAUAACUUAC-
GACAAAUU; aurora B, GUCCCAGAUAGAGAAGGAG; lamin, AC-
CAGGUGGAGCAGUAUAA (Dharmacon). Oligos were designed using
the siRNA Design program (Dharmacon) in combination with BLAST to en-
sure specificity.
For optimal RNAi, HeLa cells ( 45% confluence) were grown in the
presence of 2.5 mM thymidine for 18–24 h, and then released for 8 h af-
ter which the cells were transfected with siRNAs using Oligofectamine (In-
vitrogen) as described by Dharmacon. After 4–5 h, siRNAs were removed
and cells were grown in the presence of 2.5 mM thymidine for 12–13 h.
Finally, cells were released from the second thymidine block and fixed
10–11 h later when the majority of cells were in anaphase. Control cells
were treated with Oligofectamine alone and different oligos were used in
parallel, and distinct phenotypes were observed. The efficiency of protein
depletion was assessed by Western blotting (Fig. S2, available at http://
www.jcb.org/cgi/content/full/jcb.200501097/DC1).
Actin filaments were disrupted with 5  M LatA (Molecular Probes).
Myosin activity was inhibited using 100  M Blebbistatin (Toronto Re-
search). Aurora kinase activity was inhibited with100 nM Hesperadin
(Boehringer). Microtubules were depolymerized using 300 nM nocoda-
zole (Sigma-Aldrich). For inhibitor experiments, drugs were added for 45
min 9–10 h after release from the second thymidine block, and the cells
were collected for staining. Control treatments with solvent (DMSO or PBS)
were performed in parallel.
YFP-RhoA constructs
Full-length cDNA fragments for human and C. elegans RhoA were cloned
in frame into pEYFP C1 (BD Biosciences) to generate the YFP:HsRhoA and
YFP:CeRhoA (YFP:RhoA) fusions. A stable line expressing YFP:RhoA was
generated by G418 selection followed by cloning by limiting dilution.
Clones were screened by fluorescence microscopy and one line was ob-
tained that stably expressed the fusion protein.
Expression constructs
ECT2 and CYK-4 constructs were prepared in pCMV-(myc)3 and/or pET–
chitin binding domain (CBD) for transfection experiments and bacterial ex-
pression, respectively. The precise fragments are described in Figs. 7 and
9. The GAP domain (201–439) of mouse RhoGAP1 was cloned into
pcDNA3.1 . Bacterial proteins were expressed in BL21(DE3)-RIL. Expres-
sion was induced with IPTG for 4 h at 37 C. Bacteria were collected and
lysed by sonication in 50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2,
1% Triton X-100, 1 mM DTT, 10  g/ml leupeptin, 10  g/ml pepstatin,
and 1 mM PMSF. The lysates were centrifuged for 30 min at 4 C, and the
recombinant proteins were affinity purified with chitin beads (New En-
gland Biolabs, Inc.), washed extensively, and stored in the lysis buffer sup-
plemented with 10% glycerol at  80 C.
To assess the regulation of YFP:RhoA by GAP and GEF activity,
constructs were cotransfected with pECFP C1 (BD Biosciences) into YFP:
RhoA cells at a ratio of 5:1.SPATIAL AND TEMPORAL REGULATION OF RHOA • YÜCE ET AL. 581
Immunolocalization
Coverslips containing cells were collected and washed in warm PBS or cy-
toskeletal buffer. The cells were fixed in  20 C MeOH (to stain ECT2, tubu-
lin, MKLP1, CYK-4, and myosin II), 4% PFA (to label actin), or 4 C 10%
TCA (to stain RhoA, MKLP1, CYK-4, and myosin II [Yonemura et al., 2004])
for 15 min. Immunostaining was performed according to standard proce-
dures using Alexa 488, Alexa 568, and Cy5-labeled secondary antibodies.
Actin was labeled with rhodamine phalloidin and DNA was labeled with
Hoechst 33342. Slides were mounted in 50% glycerol, 0.1 M Tris, pH 8.8
and 4% N-propyl gallate. Slides were observed on microscopes (Axioplan;
Carl Zeiss MicroImaging, Inc.) with 40 /1.3 or 63 /1.4 objectives and
appropriate filters. Images were obtained with a CoolSnap FX camera. Im-
age processing (scaling from 12 to 8 bit, cropping, rotating, brightness and
contrast adjustment, and color combining) was performed with MetaMorph,
ImageJ, (rsb.info.nih.gov/ij/), and Adobe PhotoShop.
Live imaging
Cells were imaged with an imaging system (DeltaVision) controlled by
Softworx. HeLa cells were transfected with appropriate siRNAs for 4–5 h,
and then released into siRNA-free media and filmed with DIC optics with a
40 /1.35 objective beginning 24 h after RNAi treatment. Cells were
filmed every 15 s from metaphase or early anaphase until after cell sepa-
ration (between 40 to 100 images collected per cell). To image the YFP:
RhoA cell line, typically 300-ms exposures were collected every 15 s.
Immunoprecipitation and pull-downs
Mitotic HeLa cells were collected 10 h after release from a double thymi-
dine block. To make metaphase lysates, cells were released from the thy-
midine block for 7.5 h, at which time 40 ng/ml nocodazole was added
for a further 3.5 h. To collect cells in anaphase, the cells were released
from nocodazole and collected at the indicated times. Where applicable,
metaphase-arrested cells were treated with 100  M Roscovitine for 30
min. Cells were lysed in lysis buffer (20 mM Hepes, pH 7.2, 0.1% Triton
X-100, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 10  g/ml leupeptin, 10
 g/ml pepstatin, 1 mM PMSF, 20 mM NaF, and 200  M microcysteine).
The lysates were centrifuged 2   10 min at 14 krpm at 4 C. Antibodies
were added for 40 min, after which the immune complexes were collected
with protein A–Sepharose for 1 h at 4 C. The beads were washed exten-
sively and run on SDS-PAGE followed by Western blotting. Phosphatase
treatment was performed with   phosphatase (New England Biolabs, Inc.)
for 60 min at 30 C.
For direct binding assays, the bacterially expressed ECT2 NH2 ter-
minus was isolated in soluble form by TEV cleavage of CBD-ECT2-E5.
This fraction was incubated with CBD beads or bead-bound CBD-CSC-1
(Romano et al., 2003) or CBD-CYK-4 in 20 mM Hepes, pH 7.2, 50 mM
NaCl, 5 mM MgCl2, 0.1% Triton X-100, 1 mM DTT, 10  g/ml leupeptin,
10   g/ml pepstatin, and 1 mM PMSF for 2 h at 4 C. Beads were
washed four times in binding buffer and analyzed by SDS-PAGE and
Coomassie staining.
Online supplemental material
Online supplemental material shows the regulation of stress fibers by over-
expressed GEF and GAP domains, the rescue of myosin treatment by YFP:
RhoA in RhoA-depleted cells, and the extent of protein depletion by RNAi
and videos showing phenotypes observed by time-lapse recordings. The
online supplemental material is available at http://www.jcb.org/cgi/
content/full/jcb.200501097/DC1.
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